AKTX — Akari Therapeutics Plc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1541157 ·
Last close
$5.70
Market Cap
$13.03M
52W High
$29.32
52W Low
$3.02
ADV30
43,339
Next earnings
—
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -4,602,000 -4,807,000 38,624,000 7,694,000 20,029,000
Mar 2026 0 — -3,628,000 -14,455,000 33,889,000 2,768,000 19,509,000
Dec 2025 0 — -3,227,000 -5,298,000 47,892,000 5,203,000 19,564,000
Sep 2025 0 — -2,224,000 -6,400,000 45,376,000 2,484,000 22,689,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-10,759,000
Investing CF
—
Financing CF
$15,745,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-283,812,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-31,837,000
Pretax Income TTM
$-32,822,000
Interest Exp TTM
$985,000
Analysts
3

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -12,095,000 -17,298,000 47,892,000 19,564,000 28,328,000 -10,568,000
Dec 2024 0 -16,647,000 -19,791,000 50,562,000 28,333,000 22,229,000 -12,552,000
Dec 2023 0 -16,806,000 -10,008,000 4,355,000 4,584,000 -229,000 -16,432,000
Dec 2022 0 -23,088,000 -17,748,000 13,832,000 12,041,000 1,791,000 -21,504,000

TTM Snapshot

Revenues TTM
$1,000
NetIncome TTM
$-30,960,000
OpCashFlow TTM
—
Assets (Latest)
$38,624,000
Forward EPS
$-8.65

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $6.65 · call volume: 25 · put volume: 0

Peers — same industry

TickerNameMarket CapLastDaily %
ONCO Onconetix, Inc. $13.14M $3.00 —
ALLR Allarity Therapeutics, Inc. $13.38M $0.84 —
TVRD Tvardi Therapeutics, Inc. $13.47M $1.01 —
SYBX SYNLOGIC, INC. $13.47M $1.10 —
MTNB Matinas BioPharma Holdings, Inc. $12.57M $0.86 —

News headlines (Yahoo Finance, 1h cache)

Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform
2026-11-12 21:05 · Yahoo
Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho
2026-11-11 13:44 · Yahoo
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
2026-10-30 13:05 · Yahoo
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
2026-10-15 13:20 · Yahoo
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
2026-10-13 13:01 · Yahoo
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
2026-10-01 12:25 · Yahoo
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
2026-09-08 13:15 · Yahoo
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
2026-08-27 13:01 · Yahoo
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
2026-08-18 12:53 · Yahoo
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
2026-08-13 20:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.